The global cardiac resynchronization therapy market was valued at US$4 billion in the year 2020. The market is anticipated to reach US$5.9 billion by 2030 by growing at a compound annual growth rate ...

A total artificial heart implantation may be suggested in the event of LVAD failure. Learn what the SynCardia mechanical device could do for heart failure.

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular ...

This is further evidenced by the low incidence of recurrent myocarditis and MACE, as well as the observed stability in biventricular structure and function. The near-universal resolution of ...